GenFleet Therapeutics (Shanghai) Inc. repurchased 169,000 H-shares on 16 September 2026, spending HKD 4.22 million on‐market. The shares were bought at prices ranging from HKD 24.78 to HKD 25.22, representing a volume-weighted average of HKD 24.96 per share.

Post-transaction, the company’s outstanding share count (excluding treasury shares) fell to 351.14 million from 351.31 million, a 0.048% reduction. Treasury shares increased to 490,000, while total issued shares remained unchanged at 351.63 million.

The buyback forms part of the mandate approved on 11 May 2026, which authorises the repurchase of up to 37.04 million shares. Cumulative repurchases under this mandate now stand at 490,000 shares, equivalent to 0.13% of the company’s issued share capital at the mandate date.

In accordance with Hong Kong listing rules, GenFleet faces a moratorium on issuing new shares or selling treasury shares until 16 October 2026.